This webinar is available for free as part of the CHEST e-Learning Library.
Access this and other e-learning activities by clicking the button below.

View e-Learning Library

This webinar will explain the rationale behind combination therapy (inhaled corticosteroid/long-acting beta-2-agonist/long-acting muscarinic receptor antagonist) in chronic obstructive pulmonary disease (COPD). It will also provide a brief overview of the pivotal clinical trials for two fixed-dose triple therapies, namely, fluticasone furoate/umeclidinium/vilanterol and beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide. Patient adherence to therapy and the effect of dosing frequency on therapy adherence in COPD will be discussed as well. The webinar will also provide a list of approved combination therapies for COPD currently available in the United States.